The first stage generated a range of tools and resources for studying the nucleus in time and space including publicly available datasets and software.
The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.
The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome.
The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.
The test will be designed to run on a portable device that can ultimately be rolled out to point-of-need settings such as doctors' offices and workplaces.
UK-based ATDBio will develop new oligonucleotide-tagged microbeads for use in droplet-based single-cell RNA sequencing, to be evaluated by researchers at Oxford.
The grant will allow Weill Cornell to study genetic, social, and clinical factors that might explain why COVID-19 disproportionally affects minorities in the US.
